We are a life science innovation center that supports health tech entrepreneurs providing strategic mentorship and resources, experts and office space for growth.

OP2lysis

Op2Lysis develops the first treatment for hemorrhagic stroke a life-threatening disease that affects >1,5M people every year worldwide. Op2lysis program aims at validating the clinical safety and the efficacy of its therapeutic solution to be ready to enter advanced phases of development by 2022. Op2Lysis is a biotech company dedicated to the development of innovative products to improve the benefit of lytic treatment in stroke, the first cause of acquired handicap worldwide. Christophe GAUDIN and Jérôme PARCQ are the co-founders of Op2Lysis, which benefits from their complementary experiences and skills.

OP2lysis

Op2Lysis develops the first treatment for hemorrhagic stroke a life-threatening disease that affects >1,5M people every year worldwide. Op2lysis program aims at validating the clinical safety and the efficacy of its therapeutic solution to be ready to enter advanced phases of development by 2022. Op2Lysis is a biotech company dedicated to the development of innovative products to improve the benefit of lytic treatment in stroke, the first cause of acquired handicap worldwide. Christophe GAUDIN and Jérôme PARCQ are the co-founders of Op2Lysis, which benefits from their complementary experiences and skills.

OP2lysis

Op2Lysis develops the first treatment for hemorrhagic stroke a life-threatening disease that affects >1,5M people every year worldwide. Op2lysis program aims at validating the clinical safety and the efficacy of its therapeutic solution to be ready to enter advanced phases of development by 2022. Op2Lysis is a biotech company dedicated to the development of innovative products to improve the benefit of lytic treatment in stroke, the first cause of acquired handicap worldwide. Christophe GAUDIN and Jérôme PARCQ are the co-founders of Op2Lysis, which benefits from their complementary experiences and skills.

OP2 Innovative Drugs

OP2 Drugs SAS ("OP2") is a biotech company that aims at developing innovative life-saving drugs for unmet medical needs, especially in the cardiology field. Our first patented compound, OP2113, which targets mitochondrial dysfunction, is in the preclinical stage, with a strong scientific rationale. Based on strategic partnerships in Europe and in the US, we are generating growth and value for all stakeholders thanks to our drug candidates pipeline, in several indications. OP2 is planned to move forward to clinical in 2018. Located in Pessac, close to Bordeaux (France), OP2 Drugs is supported by Unitec (Bordeaux), managed by Frédéric Marin (CEO) and Nicolas Pineau (COO), and funded by ambitious financial players.

MANROS THERAPEUTICS

ManRos Therapeutics develops novel drug candidates acting against severe pathologies, namely cystic fibrosis, neurodegenerative disorders (Alzheimer’s disease and Down syndrome), and some renal diseases (including polycystic kidney disease). Anomalies in phosphorylation are observed in the three pathologies on which ManRos Therapeutics carries out its research: they share common targets and similar mechanisms.

aiVision